Key Highlights
- Dr. José Trevejo joins as Chief Medical Officer and Head of Clinical Pipeline Strategy.
- Brings over 15 years of drug development expertise, including recent success at Tarsus Pharmaceuticals.
- Will lead Enveda’s clinical organization and oversee the advancement of its diverse therapeutic pipeline.
Source: Business Wire
Notable Quotes
- “We are incredibly excited to welcome Dr. José Trevejo to our leadership team. His entrepreneurial spirit is further complemented by the operational excellence that he learned from his time at Vertex, Genentech and other successful biopharma companies.” — Viswa Colluru, Ph.D., CEO and Founder at Enveda
- “It is a huge honor to be joining Enveda at this transformative phase of the company. Enveda’s approach to identifying new molecules from nature using AI and then adapting them into novel medicines is compelling.” — Dr. José Trevejo, Chief Medical Officer and Head of Clinical Pipeline Strategy at Enveda Biosciences
SoHC's Take
Dr. José Trevejo’s appointment as Chief Medical Officer at Enveda Biosciences marks a significant step forward for the company. His extensive background in leading successful drug development projects, particularly his recent achievements at Tarsus Pharmaceuticals, positions him as a key asset for Enveda. Dr. Trevejo’s expertise in various therapeutic areas and his experience with FDA approvals and launches will be crucial as Enveda advances its innovative pipeline into clinical trials. This strategic hire underscores Enveda’s commitment to leveraging AI to transform natural molecules into novel medicines, potentially addressing unmet medical needs across diverse therapeutic areas.
